New research from Mass General Brigham indicates that targeting a systolic blood pressure below 120 mm Hg may significantly enhance cardiovascular health outcomes, potentially reducing the incidence of heart attacks, strokes, and heart failure more effectively than higher targets. Utilizing extensive datasets and simulation models, the study, published in the Annals of Internal Medicine, analyzed data from the Systolic Blood Pressure Intervention Trial (SPRINT) and the National Health and Nutrition Examination Survey (NHANES), among others, to evaluate the lifetime health outcomes associated with different blood pressure targets.

The findings suggest that while aiming for a more aggressive blood pressure control could lead to a greater number of cardiovascular event preventions, it also carries increased risks of treatment-related side effects, such as falls and kidney injury. Despite these concerns, the model demonstrated that the benefits of preventing cardiovascular events outweighed the risks, with the lower target remaining cost-effective at an estimated $42,000 per quality-adjusted life-year gained. This suggests that, under typical conditions, the intensive targeting of blood pressure below 120 mm Hg is a viable strategy, even when accounting for common inaccuracies in blood pressure measurements.

The implications of this study are significant for clinical practice and research paradigms in hypertension management. It encourages a reevaluation of current treatment guidelines, particularly for high-risk populations, and underscores the need for personalized treatment plans that consider both the potential benefits and risks of intensive blood pressure control. This shift may influence future drug development timelines, as pharmaceutical strategies will need to adapt to support the more aggressive management of hypertension while addressing the associated adverse effects.

Source: sciencedaily.com